2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Newly Diagnosed: new trials by email Literature Review of Newly Diagnosed trials Research Report on Newly Diagnosed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Rucaparib, Nivolumab, Placebo Oral Tablet - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 3 | Active not recruiting | pharmaand GmbH | 1097 | 2018-05-14 | 2025-06-24 |
| Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Olaparib 300mg tablets - Newly Diagnosed, Advanced Ovarian Cancer | Phase 3 | Active not recruiting | AstraZeneca | 450 | 2013-08-26 | 2025-12-10 |
Pathologic Complete Response (2) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (2) · Disease Attributes (2) · Disease Progression (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms by Site (2) · Ovarian Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Nivolumab (1) · olaparib (1) · rucaparib (1)
AstraZeneca (1) · pharmaand GmbH (1)
Australia (2) · Canada (2) · Israel (2) · Italy (2) · Japan (2) · Poland (2) · Russia (2) · South Korea (2) · Spain (2) · United Kingdom (2) · United States (2) · Belgium (1) · Brazil (1) · China (1) · Czechia (1)
Prof Kathleen Moore, MD (1) · Prof Paul DiSilvestro, MD (1)
PMID 30345884, PMID 33862001, PMID 34593565, PMID 34715071, PMID 35170751, PMID 35658487, PMID 36082969, PMID 39695768, PMID 41115469
2017 (1)